CoChat

Racial and ethnic disparities in the uptake of SGLT2is and GLP-1RAs among Medicare beneficiaries with type 2 diabetes and heart failure, atherosclerotic cardiovascular disease and chronic kidney disease, 2013–2019

Open access
Wang, Eric, Patorno, Elisabetta, Khosrow-Khavar, Farzin, Crystal, Stephen, Dave, Chintan V. · 2025 · Diabetologia

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index; 15 of the 22 sources its claims cite were checked for support.

Abstract

This retrospective Medicare study examined racial and ethnic disparities in initiation of SGLT2is and GLP-1RAs among older adults with type 2 diabetes across cardiorenal-risk subgroups.

Overview

CoChat Summary

TL;DR

In a retrospective cohort of Medicare fee-for-service beneficiaries aged 65+ with type 2 diabetes, Black participants had lower uptake of SGLT2 inhibitors and GLP-1 receptor agonists than White participants, and Hispanic participants had lower GLP-1RA uptake and some lower SGLT2i uptake depending on cohort. These disparities narrowed over 2013–2019 but did not disappear by 2019.

Key findings

  • The final cohort included 838,361 glucose-lowering therapy initiation episodes: 152,214 with heart failure (HF), 412,890 with ASCVD, 154,849 with CKD, and 350,707 with no recorded cardiorenal conditions.
  • Compared with White participants, Black participants had lower adjusted odds of initiating SGLT2is across all cohorts: HF OR 0.65, ASCVD OR 0.67, CKD OR 0.68, and no cardiorenal conditions OR 0.76.
  • For Black participants, SGLT2i disparities attenuated from 50–60% lower odds in 2013 to 17–18% lower odds in 2019; similar adjusted disparities were seen for GLP-1RA initiation (HF OR 0.67, ASCVD OR 0.67, CKD OR 0.70, no cardiorenal conditions OR 0.71).
  • Hispanic participants had similar adjusted odds of SGLT2i initiation to White participants in the HF and CKD cohorts, but lower odds in ASCVD (OR 0.94) and no cardiorenal conditions (OR 0.93); Hispanic participants had lower GLP-1RA initiation in all cohorts (ORs 0.89, 0.84, 0.84, 0.75).
  • Black and Hispanic participants had higher odds of initiating DPP4 inhibitors than White participants; the paper reports HF 1.25, ASCVD 1.36, and CKD 1.32 for Hispanic participants, and says the same pattern held for Black participants.

Methods

  • Retrospective cohort study using 2013–2019 Medicare fee-for-service Part D data; eligible participants were ≥65 years with type 2 diabetes, continuous enrollment for at least 1 year, and no prior use of the study medication in the baseline period.
  • Participants were grouped into four non-mutually exclusive cohorts: HF, ASCVD, CKD, or no recorded cardiorenal conditions; race/ethnicity was classified as non-Hispanic White, non-Hispanic Black, Hispanic, or other.
  • Main analysis used multinomial logistic regression to model initiation of SGLT2is, GLP-1RAs, DPP4is, or sulfonylureas, with sulfonylureas as the reference; models adjusted for demographic, clinical, and county-level social vulnerability factors, and analyses were stratified by cohort and calendar year.

Limitations

  • The paper states that the 365-day washout may have missed prior use before baseline, that social vulnerability was measured at county level rather than individual level, that the findings are generalizable only to older Medicare fee-for-service beneficiaries, that formulary differences could not be accounted for, and that data on diabetes duration, disease control, and specialist visits were unavailable.
  • The study ended in 2019, so it could not assess more recent changes after 2019/2020 guideline updates or the impact of COVID-19.
  • Evident from the text: the “other race and ethnicity” group combined several populations and people with missing race data, which limited more granular assessment.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s00125-024-06321-2

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Temporal patterns (2013–2019) in the proportions of new initiations of SGLT2is by race and ethnicity and cardiorenal condition: (a) comorbid HF; (b) comorbid ASCVD; (c) comorbid CKD; (d) no comorbid cardiorenal conditions. 1: EMPA-REG OUTCOME trial results published, highlighting the cardiovascular benefits of SGLT2is [6]. 2: ADA guideline shifts, indicating SGLT2is and GLP1-RAs as preferred therapies for individuals with type 2 diabetes and comorbid cardiovascular conditions [36]. 3: CREDENCE trial results published, highlighting SGLT2i benefits in CKD [37]
Fig. 1 Temporal patterns (2013–2019) in the proportions of new initiations of SGLT2is by race and ethnicity and cardiorenal condition: (a) comorbid HF; (b) comorbid ASCVD; (c) comorbid CKD; (d) no comorbid cardiorenal conditions. 1: EMPA-REG OUTCOME trial results published, highlighting the cardiovascular benefits of SGLT2is [6]. 2: ADA guideline shifts, indicating SGLT2is and GLP1-RAs as preferred therapies for individuals with type 2 diabetes and comorbid cardiovascular conditions [36]. 3: CREDENCE trial results published, highlighting SGLT2i benefits in CKD [37]CC BY · PubMed Central
Fig. 2 Temporal patterns (2013–2019) in the proportions of new initiations of GLP1 RAs by race and ethnicity and cardiorenal condition: (a) comorbid HF; (b) comorbid ASCVD; (c) comorbid CKD; (d) no comorbid cardiorenal conditions. 1: LEADER and SUSTAIN-6 trial results published, highlighting the cardiovascular benefits of GLP1-RAs [38, 39]. 2: ADA guideline shifts, indicating SGLT2is and GLP1-RAs as preferred therapies for individuals with type 2 diabetes and comorbid cardiovascular conditions [36]. 3: REWIND trial results published, highlighting the cardiovascular benefits of GLP-1RAs [40]
Fig. 2 Temporal patterns (2013–2019) in the proportions of new initiations of GLP1 RAs by race and ethnicity and cardiorenal condition: (a) comorbid HF; (b) comorbid ASCVD; (c) comorbid CKD; (d) no comorbid cardiorenal conditions. 1: LEADER and SUSTAIN-6 trial results published, highlighting the cardiovascular benefits of GLP1-RAs [38, 39]. 2: ADA guideline shifts, indicating SGLT2is and GLP1-RAs as preferred therapies for individuals with type 2 diabetes and comorbid cardiovascular conditions [36]. 3: REWIND trial results published, highlighting the cardiovascular benefits of GLP-1RAs [40]CC BY · PubMed Central
Fig. 3 Adjusted multinomial regression models of the odds of initiating second-line therapies per year by comorbid cardiorenal condition and drug class for Black vs White participants, with SUs as the reference group: (a) comorbid HF; (b) comorbid ASCVD; (c) comorbid CKD; (d) no comorbid cardiorenal conditions
Fig. 3 Adjusted multinomial regression models of the odds of initiating second-line therapies per year by comorbid cardiorenal condition and drug class for Black vs White participants, with SUs as the reference group: (a) comorbid HF; (b) comorbid ASCVD; (c) comorbid CKD; (d) no comorbid cardiorenal conditionsCC BY · PubMed Central
Fig. 4 Adjusted multinomial regression models of the odds of initiating second-line therapies per year by comorbid cardiorenal condition and drug class for Hispanic vs White participants, with SUs as the reference group: (a) comorbid HF; (b) comorbid ASCVD; (c) comorbid CKD; (d) no comorbid cardiorenal conditions
Fig. 4 Adjusted multinomial regression models of the odds of initiating second-line therapies per year by comorbid cardiorenal condition and drug class for Hispanic vs White participants, with SUs as the reference group: (a) comorbid HF; (b) comorbid ASCVD; (c) comorbid CKD; (d) no comorbid cardiorenal conditionsCC BY · PubMed Central

Verification

Claims the paper makes

5 Valid · 2 Not valid · 2 Not checked · 49 Own results and interpretations

34 more claims

Create a free account to see all 58 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 12
  • It may state two separate claims as one. 9

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 40 references

Cited by

See all 14

Metadata

Authors
Wang, E., Patorno, E., Khosrow-Khavar, F., Crystal, S., & Dave, C. V.
Affiliations
  • Rutgers, The State University of New Jersey (US)
  • Brigham and Women's Hospital (US)
Corresponding author
  • Wang, Eric
  • Dave, Chintan V.
Venue
Diabetologia
Published
2024-11-08
Volume
68
Issue
1
Pages
94-104
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W4404186491
Cited by
14
References
40
Citations by year
2026: 11 · 2025: 3
FWCI
4.58
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetologia (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
NIH (1R01HL163163)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
racial and ethnic disparities, SGLT2 inhibitors, GLP-1 receptor agonists, type 2 diabetes, heart failure, atherosclerotic cardiovascular disease, chronic kidney disease, Medicare beneficiaries, older adults, black-white disparities, DPP-4 inhibitors, sulfonylureas
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, White, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Aged, 80 and over, Black or African American, Diabetes Mellitus, Type 2, Ethnicity, Female, Medicare, Heart Failure, Hispanic or Latino, Humans, Male, Retrospective Studies, United States, Atherosclerosis, Renal Insufficiency, Chronic, Healthcare Disparities

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.